ArticleIntensive care medicine2018
Impact of a multifaceted prevention program on ventilator-associated pneumonia including selective oropharyngeal decontamination.
Article in Intensive care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- The effect of selective decontamination on antimicrobial resistance in intensive care patients: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation.The Cochrane database of systematic reviews · 2021Pooled it
- The effect of an infection control guideline on the incidence of ventilator-associated pneumonia in patients admitted to the intensive care units.BMC infectious diseases · 2023Trial
- Pioneering infection prevention and control education through simulation-based learning: impact on knowledge and skills in nursing students in Tunisia.BMC nursing · 2026Article
- Sustained effect of a multifaceted VAP prevention program over more than seven years including the COVID-19 pandemic.Antimicrobial resistance and infection control · 2025Article
- Impact of Multifaceted Interventions Including Waterless Patient Care on Endemic Occurrence ofPathogens (Basel, Switzerland) · 2025Article
- A multimedia tool for infection prevention and control practices in the intensive care unit: a participatory interventional before-after study.Infection prevention in practice · 2025Article
- Oral care medications for the prevention and treatment of ventilator-associated pneumonia in intensive care unit.Frontiers in oral health · 2025Review
- Rebound Inverts theAntibiotics (Basel, Switzerland) · 2024Article
- Molecular mechanism of honeysuckle + forsythia in treatment of acute lung injury based on network pharmacology.Biomedical reports · 2024Article
- The ongoing challenge of ventilator-associated pneumonia: epidemiology, prevention, and risk factors for mortality in a secondary care hospital intensive care unit.Infection prevention in practice · 2023Article
- Prevention of ventilator-associated pneumonia through care bundles: A systematic review and meta-analysis.Journal of intensive medicine · 2023Article
- The Impact of Care Bundles on Ventilator-Associated Pneumonia (VAP) Prevention in Adult ICUs: A Systematic Review.Antibiotics (Basel, Switzerland) · 2023Review
- [Update of the recommendations of the Pneumonia Zero project].Enfermeria intensiva · 2022Review
- Effect of a multimodal strategy for prevention of nosocomial influenza: a retrospective study at Grenoble Alpes University Hospital from 2014 to 2019.Antimicrobial resistance and infection control · 2022Article
- Ventilator-associated pneumonia in PICU - how are we doing?The Southern African journal of critical care : the official journal of the Critical Care Society · 2022Article
- Outbreak of Pseudomonas aeruginosa producing VIM carbapenemase in an intensive care unit and its termination by implementation of waterless patient care.Critical care (London, England) · 2021Article
- Characterization of the virulence of Pseudomonas aeruginosa strains causing ventilator-associated pneumonia.BMC infectious diseases · 2020Article
- Preparedness and Reorganization of Care for Coronavirus Disease 2019 Patients in a Swiss ICU: Characteristics and Outcomes of 129 Patients.Critical care explorations · 2020Article
- The zero-VAP sophistry and controversies surrounding prevention of ventilator-associated pneumonia.Intensive care medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD).
methodsWe compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for > 48 h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality.
resultsPre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29-0.65; P < 0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08-0.27; P < 0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38-0.87; P < 0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13-0.72; P < 0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P < 0.028), median duration of MV (from 7.1 to 6.4 days; P < 0.003) and ICU mortality (from 16.2 to 13.5%; P < 0.049) for patients ventilated > 48 h between the pre- and post-intervention periods.
conclusionsOur preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.